Oct 3 (Reuters) – Shares of LogicBio Therapeutics (LOGC.O) skyrocketed on Monday after Britain’s AstraZeneca’s (AZN.L) said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Here is an SEO-optimized WordPress article about the Apollo-Evri acquisition deal: Apollo's £2.7bn Acquisition of Evri - IntroductionIn a major strategic move, Apollo Global Management has struck a...
21 Invest Mulls Sale of $500M Eye-Care Firm Sifi - IntroductionIn a move that could reshape the eye-care industry, Italian private equity firm 21 Invest is reportedly considering the sale of Sifi,...
Shares of Credit Suisse and UBS led losses on the pan-European Stoxx 600 index on Monday morning, shortly after the latter secured a 3 billion Swiss franc ($3.2 billion) "emergency rescue" of its...
ZURICH, March 20 (Reuters) - Switzerland awoke on Monday to a new era after UBS (UBSG.S) agreed to take over the ailing Credit Suisse (CSGN.S), with a bank employee association saying it was "deeply...